Radiolabeled vitamins as the potential diagnostic probes for targeted tumor imaging

Shahrokhi, Pejman; Farahani, Arezou Masteri; Tamaddondar, Mohammad

doi:10.1016/j.bioorg.2022.105717

Cited by 3 publications

(4 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Radioligand Therapy (Rlt)mentioning

confidence: 99%

“…In cancer cells, TCII facilitates cell uptake by binding to upregulated specific receptors (i.e., CD320). Investigations have been conducted on various radiolabeled cobalamin derivatives, mostly using γ-emitters, both in preclinical models and in patients with different tumor types that express TCII [ 227 ]. One example of a positron-emitting cobalamin derivative (with 89 Zr) has also been reported [ 238 ].…”

Section: Radioligand Therapy (Rlt)mentioning

confidence: 99%

“…As a result, targeting these receptors has become an appealing approach. Numerous studies have shown that vitamin-based bioconjugates, particularly folate, have significant potential for imaging and therapy [227]. Biotin, a water-soluble vitamin, also referred as vitamin B7 or H, weighs 244 Daltons and plays a significant role in various metabolic processes, including gluconeogenesis and cell growth stimulation.…”

Section: Vitaminsmentioning

confidence: 99%

See 2 more Smart Citations

Clinical Advances and Perspectives in Targeted Radionuclide Therapy

Lepareur,

Ramée,

Mougin-Degraef

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Targeted radionuclide therapy has become increasingly prominent as a nuclear medicine subspecialty. For many decades, treatment with radionuclides has been mainly restricted to the use of iodine-131 in thyroid disorders. Currently, radiopharmaceuticals, consisting of a radionuclide coupled to a vector that binds to a desired biological target with high specificity, are being developed. The objective is to be as selective as possible at the tumor level, while limiting the dose received at the healthy tissue level. In recent years, a better understanding of molecular mechanisms of cancer, as well as the appearance of innovative targeting agents (antibodies, peptides, and small molecules) and the availability of new radioisotopes, have enabled considerable advances in the field of vectorized internal radiotherapy with a better therapeutic efficacy, radiation safety and personalized treatments. For instance, targeting the tumor microenvironment, instead of the cancer cells, now appears particularly attractive. Several radiopharmaceuticals for therapeutic targeting have shown clinical value in several types of tumors and have been or will soon be approved and authorized for clinical use. Following their clinical and commercial success, research in that domain is particularly growing, with the clinical pipeline appearing as a promising target. This review aims to provide an overview of current research on targeting radionuclide therapy.

show abstract

Section: Radioligand Therapy (Rlt)mentioning

confidence: 99%

Section: Radioligand Therapy (Rlt)mentioning

confidence: 99%

Section: Vitaminsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Advances and Perspectives in Targeted Radionuclide Therapy

Lepareur,

Ramée,

Mougin-Degraef

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Дальнейшее развитие технологий визуализации опухолей и мониторинга эффективности лечения в первую очередь определяется наличием новых высокоспецифичных РФП [12]. В течение последних двух десятилетий в качестве потенциальных радиотрейсеров исследуются и меченые витамины, и их производные.…”

unclassified

Synthesis and in Vitro Study of Fluorine-18 Labelled Pyridoxine (Vitamin B6) Stability

Vaulina¹,

Kuznetsova²,

Fedorova³

et al. 2022

IJAFR (МЖПФИ)

View full text Add to dashboard Cite

Витамин В6 является одним из важнейших витаминов, необходимым для ключевых стадий клеточного метаболизма, участвующим в качестве кофактора в основных биохимических реакциях. In vitro он существует в виде шести химически близких структур, содержащих в основе пиридиновое кольцо. В группе методов молекулярной визуализации позитронная эмиссионная томография (ПЭТ) занимает ведущее место. В клинической практике ПЭТ чаще используется в определении локализации, стадии и контроля терапии при многих заболеваниях, в том числе онкологических. Использование витаминов как молекулярных «переносчиков» для доставки лекарств к опухоли является мощной стратегией терапии злокачественных и воспалительных заболеваний; на этой же основе возможна и разработка биомаркеров для визуализации процессов доставки методом ПЭТ. В данной работе впервые предложен метод радиосинтеза производного 2-[ 18 F]фторметил-пиридоксина, производного витамина В6, и проведены первые исследования стабильности этого соединения в плазме крови человека. Радиолиганд был получен прямым нуклеофильным замещением ацетильной защитной группы на фтор-18 с радиохимической чистотой ≥ 95 %. Проведены предварительные исследования устойчивости нового радиотрейсера в плазме крови человека, показавшие, что после 40 мин инкубации лишь 40 % производного 2-[ 18 F]фторметил-пиридоксина остается в неизменной форме. Таким образом, на данном этапе не удается сделать вывод о возможности использования предложенного радиолиганда в качестве потенциального ПЭТ радиотрейсера.

show abstract

Clinical Advances and Perspectives in Targeted Radionuclide Therapy

Lepareur,

Ramée,

Mougin-Degraef

et al. 2023

Preprint

View full text Add to dashboard Cite

Targeted radionuclide therapy is become increasingly prominent as a nuclear medicine subspe-cialty. For many decades, treatment with radionuclides has been mainly restricted to the use of iodine-131 in thyroid disorders. Currently, radiopharmaceuticals, consisting of a radionuclide coupled to a vector that binds to a desired biological target with high specificity, are being de-veloped. The objective is to be as selective as possible at the tumor level, while limiting the dose received at the healthy tissue level. In recent years, a better understanding of molecular mecha-nisms of cancer, as well as the appearance of innovative targeting agents (antibodies, peptides, small molecules) and the availability of new radioisotopes, have enabled considerable advances in the field of vectorized internal radiotherapy with a better therapeutic efficacy, radiation safety and personalized treatments. For instance, targeting the tumor microenvironment, instead of the cancer cells, now appears as particularly attractive. Several radiopharmaceuticals for therapeutic targeting have shown clinical value in severals types of tumors and have been or will soon be approved and authorized for clinical use.

show abstract

Radiolabeled vitamins as the potential diagnostic probes for targeted tumor imaging

Cited by 3 publications

References 75 publications

Clinical Advances and Perspectives in Targeted Radionuclide Therapy

Clinical Advances and Perspectives in Targeted Radionuclide Therapy

Synthesis and in Vitro Study of Fluorine-18 Labelled Pyridoxine (Vitamin B6) Stability

Clinical Advances and Perspectives in Targeted Radionuclide Therapy

Contact Info

Product

Resources

About